[1] GOTWALS P, CAMERON S, CIPOLLETTA D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy
[J]. Nature Reviews Cancer, 2017, 17(5): 286-301.

[2] SU Z, XIAO D, XIE F, et al. Antibody–drug conjugates: Recent advances in linker chemistry
[J]. Acta Pharmaceutica Sinica B, 2021, 11(12): 3889-3907.

[3] ZIAEI E, PAIVA I M D, YAO S J, et al. Peptide–Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice
[J]. Molecular Pharmaceutics, 2023, 20(7): 3570-3577.

[4] WANG Y, CHEETHAM A G, ANGACIAN G, et al. Peptide–drug conjugates as effective prodrug strategies for targeted delivery
[J]. Advanced Drug Delivery Reviews, 2017, 110-111: 112-126.

[5] LIN X, TAN S M, LAW S K A, et al. Two types of transmembrane homomeric interactions in the integrin receptor family are evolutionarily conserved
[J]. Proteins: Structure, Function, and Bioinformatics, 2006, 63(1): 16-23.

[6] CHATZISIDERI T, LEONIDIS G, KARAMPELAS T, et al. Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine
[J]. Journal of Medicinal Chemistry, 2022, 65(1): 271-284.

[7] VRETTOS E I, KARAMPELAS T, SAYYAD N, et al. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer
[J]. European Journal of Medicinal Chemistry, 2021, 211: 113018.

[8] VATS K, SATPATI D, SHARMA R, et al. 99m T c‐labeled NGR ‐chlorambucil conjugate,99m T c‐ HYNIC ‐ CLB ‐c( NGR ) for targeted chemotherapy and molecular imaging
[J]. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60(9): 431-438.

[9] SHOKRI B, ZARGHI A, SHAHHOSEINI S, et al. Design, synthesis and biological evaluation of peptide‐NSAID conjugates for targeted cancer therapy
[J]. Archiv der Pharmazie, 2019, 352(8): 1800379.

[10] AL MUSAIMI O. Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989
[J]. Cancers, 2024, 16(5): 1032.

[11] SALNER A L, BLANKENSHIP B, DUNNACK H, et al. Lutetium Lu-177 Dotatate Flare Reaction
[J]. Advances in Radiation Oncology, 2021, 6(1): 100623.

[12] DARWISH S, SADEGHIANI N, FONG S, et al. Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide
[J]. European Journal of Medicinal Chemistry, 2019, 161: 594-606.

[13] ZHAO S, YU N, HAN H, et al. Advances in acid-degradable and enzyme-cleavable linkers for drug delivery
[J]. Current Opinion in Chemical Biology, 2025, 84: 102552.

[14] RÉGINA A, DEMEULE M, CHÉ C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2
[J]. British Journal of Pharmacology, 2008, 155(2): 185-197.

[15] BARGH J D, ISIDRO-LLOBET A, PARKER J S, et al. Cleavable linkers in antibody–drug conjugates
[J]. Chemical Society Reviews, 2019, 48(16): 4361-4374.

[16] ALAS M, SAGHAEIDEHKORDI A, KAUR K. Peptide–Drug Conjugates with Different Linkers for Cancer Therapy
[J]. Journal of Medicinal Chemistry, 2021, 64(1): 216-232.

[17] HAN J, FU J, YANG Q, et al. Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents
[J]. European Journal of Medicinal Chemistry, 2020, 198: 112389.

[18] LI S, ZHAO H, MAO X, et al. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate
[J]. Pharmaceutical Research, 2019, 36(12): 168.

[19] ZHAO L, WEN X, XU W, et al. Clinical Evaluation of68 Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin αv β3 in Various Cancer Types
[J]. Journal of Nuclear Medicine, 2023, 64(8): 1210-1217.

[20] HANKE N, TEIFEL M, MOJ D, et al. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis
[J]. Cancer Chemotherapy and Pharmacology, 2018, 81(2): 291-304.

[21] MAHALINGAM D, PEGUERO J, CEN P, et al. A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
[J]. Cancers, 2019, 11(6): 833.

[22] DEMEULE M, CHARFI C, CURRIE J, et al. TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer
[J]. Cancer Science, 2021, 112(10): 4317-4334.

[23] KUMTHEKAR P, TANG S C, BRENNER A J, et al. ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
[J]. Clinical Cancer Research, 2020, 26(12): 2789-2799.

[24] WHALEN K A, WHITE B H, QUINN J M, et al. Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
[J]. Molecular Cancer Therapeutics, 2019, 18(11): 1926-1936.

[25] WERLE M, BERNKOP-SCHNÜRCH A. Strategies to improve plasma half life time of peptide and protein drugs
[J]. Amino Acids, 2006, 30(4): 351-367.

[26] LAU J, BLOCH P, SCHÄFFER L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
[J]. Journal of Medicinal Chemistry, 2015, 58(18): 7370-7380.

[27] ZHENG S, CAI Y, HONG Y, et al. Legumain/pH dual-responsive lytic peptide–paclitaxel conjugate for synergistic cancer therapy
[J]. Drug Delivery, 2022, 29(1): 1764-1775.